CheckMate 648 Update Showcases Long-Term Survival Benefit With Frontline Nivolumab in ESCC
January 24th 2023The median overall survival with nivolumab plus chemotherapy was 12.8 months, vs 10.7 months with chemotherapy alone, in patients with treatment-naïve advanced esophageal squamous cell carcinoma.
POSITIVE Study Findings Shift Conversations on Pregnancy in ER+ Breast Cancer
January 6th 2023Jamie Carroll, APRN, CNP, MSN, weighs in on how findings from the POSITIVE study may change dialogue surrounding pregnancy for women with estrogen receptor–positive breast cancer who wish to pause adjuvant therapy.
Rucaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer
December 30th 2022Maintenance therapy with rucaparib monotherapy improved progression-free survival compared with placebo. However, the treatment also significantly elevated anemia and neutropenia rates in this setting.
Second-Line Liso-Cel Continues to Improve Event-Free Survival in Large B-Cell Lymphoma
December 25th 2022In the second line setting, lisocabtagene maraleucel (liso-cel; Breyanzi) significantly reduced the risk of an event for patients with high-risk relapsed/refractory large B-cell lymphoma, compared with standard-of-care chemoimmunotherapy induction.